| Filed | Description | |
|---|---|---|
| 2/19/26 | 1.01 Material Agreement | → |
| 1/7/26 | 1.012.03 Material Agreement · New Debt Obligation | → |
| 1/10/25 | 1.01 Material Agreement | → |
| 8/16/23 | 1.01 Material Agreement | → |
| 7/5/23 | 1.012.03 Material Agreement · New Debt Obligation | → |
| 3/25/22 | 1.01 Material Agreement | → |
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression.